Pamidronate treatment of severe osteogenesis imperfecta in a newborn infant
Pamidronate treatment of severe osteogenesis imperfecta in a newborn infant
复制标题
DOI：
10.1023/a:1022099425316
复制
发表时间：
2002-11-01
影响因子：
4.2
通讯作者：
Hwu, WL
中科院分区：
文献类型：
--
作者：
Chien, YH;Chu, SY;Hwu, WL
双膦酸盐治疗已用于2个月大的婴儿（Plotkin et al . 2000）。虽然我们警惕并发症，但症状性低钙血症仍然发生。这表明婴儿在他们生命的第一个月有脆弱的钙平衡。因此，我们建议接受双膦酸盐治疗的新生儿静脉补钙可能是必要的，特别是在口服摄入不安全的情况下。
Bisphosphonate treatment has been used in infants from 2 months of age (Plotkin et al 2000). Although we were alert for complications, symptomatic hypocalcaemia still occurred. This indicates that infants in their first month of life have fragile calcium balance. Therefore, we suggest that intravenous calcium supplements may be necessary for neonates receiving bisphosphonate treatment, especially when oral intake is not secured.